Alkaline phosphatase agents for treatment of neurodevelopmental disorders

The method of any of the above claims, wherein the AP-based agent is intestinal alkaline phosphate (IAP).

The method of any of the above claims, wherein the neurodevelopmental disorder is selected from autism spectrum disorder (ASD), schizophrenia, attention deficit hyperactivity disorder (ADHD), schizoaffective disorder, and bipolar affective disorder.

The method of any of the above claims, wherein the subject is a pregnant woman.

The method of any of the above claims, wherein the AP-based agent is administered orally.

The method of any of the above claims, wherein the AP-based agent is IAP selected from human IAP (hIAP), calf IAP (cIAP), and bovine IAP (bIAP), or variants thereof.

The method of any of the above claims, wherein the AP-based agent comprises an amino acid sequence having at least 95%, or 97%, or 99% sequence identity with any one of SEQ ID NOs:

• 1-11 and 17-18.

The method of any of the above claims, wherein the AP-based agent is bIAP II or a variant thereof.

The method of any of the above claims, wherein the AP-based agent comprises an amino sequence having at least 95% sequence identity with SEQ ID NO:

• 2 (bIAP II).

The method of any of the above claims, wherein the AP-based agent comprises an amino sequence having at least 97% sequence identity with SEQ ID NO:

• 2 (bIAP II).

The method of any of the above claims, wherein the AP-based agent comprises the amino sequence of SEQ ID NO:

• 2 (bIAP II).

The method of any of the above claims, wherein the AP-based agent is bIAP IV or a variant thereof.

The method of any of the above claims, wherein the AP-based agent comprises an amino sequence having at least 95% sequence identity with SEQ ID NO:

• 3 (bIAP IV).

The method of any of the above claims, wherein the AP-based agent comprises an amino sequence having at least 97% sequence identity with SEQ ID NO:

• 3 (bIAP IV).

The method of any of the above claims, wherein the AP-based agent comprises the amino sequence of SEQ ID NO:

• 3 (bIAP IV).

The method of any of the above claims, wherein the AP-based agent comprises a specific activity of at least about 100 U/mg to about 20,000 U/mg.

The method of any of the above claims, wherein the AP-based agent is stable and/or active in the GI tract, in one or more of the mouth, esophagus, stomach, duodenum, small intestine, jejunum, ileum, large intestine, colon, cecum, and rectum.

The method of any of the above claims, wherein the AP-based agent is substantially active at a pH of about 6.0 to about 12.

The method of any of the above claims, wherein the AP-based agent is stable in chyme.

Use of an AP-based agent for the treatment or prevention of a neurodevelopmental disorder in a subject in need thereof.

The use of an AP-based agent for the preparation of a medicament for the treatment or prevention of a neurodevelopmental disorder in a subject in need thereof.